Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III Study Against COVID-19
Shots:
- The P-III trial evaluates REGEN-COV (1200mg, SC) vs PBO in a ratio (1:1) in patients who lived in the same household with COVID-19 patients diagnosed within the prior 4 days. The trial is jointly run with NIAID
- The results showed an 81.6% reduction in risk of COVID-19 during a pre-specified follow-up period b/w 2-8mos. & 81.5% reduction @8mos. after receiving REGEN-COV, no deaths in any treatment group @8mos. & no new safety signals were observed
- The US FDA has authorized the use of REGEN-COV in high-risk patients or post-exposure prophylaxis settings. Regeneron & Roche collaborated to boost the supply of Ab cocktails & Roche responsible for development & distribution outside the US
Ref: Regeneron | Image: Regeneron
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com